Market cap
$385 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
42.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
109,774,597
10 Years Aggregate
CFO
$-777.85 Mln
EBITDA
$-996.40 Mln
Net Profit
$-1,088.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
| 4.3 | 14.7 | 23.6 | 3.4 | -38.6 | -34.7 | -18.1 |
|
BSE Sensex*
| -8.9 | 1.4 | 1.5 | -4.5 | 5.9 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
| -72.1 | -57.8 | 53.1 | -10.4 | -60.2 | 140.9 | 53.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
3.7 | 385.3 | 0.0 | -17.3 | -- | -5.3 | -- | 1.0 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 250.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Rocket Pharmaceuticals (RCKT)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It... develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. Read more
-
CEO & Director
Dr. Gaurav D. Shah M.D.
-
CEO & Director
Dr. Gaurav D. Shah M.D.
-
Headquarters
Cranbury, NJ
-
Website
FAQs for Rocket Pharmaceuticals (RCKT)
What is the current share price of Rocket Pharmaceuticals Inc (RCKT) Today?
The share price of Rocket Pharmaceuticals Inc (RCKT) is $3.66 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Rocket Pharmaceuticals Inc (RCKT) has given a return of -38.64% in the last 3 years.
What is the current PB & PE ratio of Rocket Pharmaceuticals Inc (RCKT)?
Since, TTM earnings of Rocket Pharmaceuticals Inc (RCKT) is negative, P/E ratio is not available.
The P/B ratio of Rocket Pharmaceuticals Inc (RCKT) is 1.04 times as on 21-Aug-2026, a 81 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.75 |
1.41 |
2024 |
-4.74 |
2.65 |
2023 |
-10.25 |
5.11 |
2022 |
-6.43 |
2.91 |
2021 |
-8.32 |
3.10 |
What is the 52 Week High and Low of Rocket Pharmaceuticals Inc (RCKT)?
The 52-week high and low of Rocket Pharmaceuticals Inc (RCKT) are Rs 5.45 and Rs 2.53 as of 27-Aug-2026.
What is the market cap of Rocket Pharmaceuticals Inc (RCKT)?
Rocket Pharmaceuticals Inc (RCKT) has a market capitalisation of $ 385 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Rocket Pharmaceuticals Inc (RCKT)?
Before investing in Rocket Pharmaceuticals Inc (RCKT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.